TP53 and cancer: Oncogenic activation of RAS is well known to reduce the surface expression of antigen-presenting major histocompatibility complexes (MHC) on cancer cells, and such downregulation enables the cells to evade the immune response.30 Other downregulated pathways included the p53 signalling pathway and genes encoding cell adhesion molecules (Supplementary Fig. 3B, C).